While CGRP-targeted therapies have revolutionized migraine treatment, patients suffering from rarer headache disorders — including cluster headache, new daily persistent headache (NDPH), tension-type headache (TTH), and trigeminal autonomic cephalalgias (TACs) — remain largely overlooked by researchers, clinicians, and funders alike. Cluster headache, often called the "suicide headache," produces rapidly escalating, unilateral orbital pain so severe that roughly 40% of patients experience high levels of suicidal ideation. Despite this, an accurate diagnosis can take 7–10 years, with patients frequently misdiagnosed with migraine, sinusitis, or eye disorders.

The research funding gap is stark. In 2025, the NIH directed just 0.1% of its $48 billion budget to headache disorders — mostly toward migraine. Over 25 years, only ~$25 million has gone toward cluster headache research. Meanwhile, a UK analysis found that MS received £137 million in public funding since 2006, while cluster headache received none — despite comparable disease burden. Emerging treatments like psilocybin, noninvasive vagus nerve stimulation, and PACAP-targeting drugs offer some hope, alongside growing global genetic research efforts.

By the Numbers:

• ~40% of cluster headache patients experience high levels of suicidal ideation
• Average diagnosis delay: 7–10 years
• NIH headache research funding: just 0.1% of a $48B budget
• ~$25M invested in cluster headache research over 25 years
• TTH caused 4.6 million years lived with disability in 2021
• Cluster headache patients globally endure 3.1 million person-days/year of pain rated 9/10

Why it matters: Rare headache disorders impose enormous suffering and disability, yet remain drastically underfunded and understudied. Without greater investment and clinical awareness, millions of patients will continue to face years of misdiagnosis, ineffective treatment, and profound psychological burden.